» Articles » PMID: 34790887

Review of Current Controversial Issues in Clinical Trials

Overview
Journal Gen Psychiatr
Specialty Psychiatry
Date 2021 Nov 18
PMID 34790887
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

In clinical development, adequate and well-controlled randomised clinical trials are usually conducted to evaluate the safety and efficacy of test treatment under investigation. The purpose is to ensure that there is an accurate and reliable assessment of test treatment under study. In practice, however, some controversial issues inevitably appear despite the compliance of good clinical practice. These debatable issues include, but are not limited to, (1) appropriateness of hypotheses for clinical investigation, (2) feasibility of power calculation for sample size requirement, (3) integrity of randomisation/blinding, (4) strategy for clinical endpoint selection, (5) demonstrating effectiveness or ineffectiveness, (6) impact of protocol amendments and (7) independence of independent data monitoring committee. In this article, these controversial issues are discussed. The impact of these issues in evaluating the safety and efficacy of the test treatment under investigation is also assessed. Recommendations regarding possible resolutions to these issues are provided whenever possible.

Citing Articles

SAS macro programme for Bang's Blinding Index to assess and visualise the success of blinding in randomised controlled trials.

Qin Z, Yu Y, Gu H, Shi D, Wang Z, Wu J Gen Psychiatr. 2024; 37(6):e101578.

PMID: 39660039 PMC: 11629010. DOI: 10.1136/gpsych-2024-101578.


Cardiac magnetic resonance imaging-derived septum swing index detects pulmonary hypertension: A diagnostic study.

He M, Jiang R, Fei-Sun , Cao J, Wang L, Shi J J Transl Int Med. 2023; 11(4):459-467.

PMID: 38130640 PMC: 10732575. DOI: 10.2478/jtim-2023-0114.

References
1.
Filozof C, Chow S, Dimick-Santos L, Chen Y, Williams R, Goldstein B . Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. Hepatol Commun. 2018; 1(7):577-585. PMC: 5721443. DOI: 10.1002/hep4.1079. View

2.
Chow S, Chang M, Pong A . Statistical consideration of adaptive methods in clinical development. J Biopharm Stat. 2005; 15(4):575-91. DOI: 10.1081/BIP-200062277. View

3.
Chow S, Shao J, Hu O . Assessing sensitivity and similarity in bridging studies. J Biopharm Stat. 2002; 12(3):385-400. DOI: 10.1081/bip-120014567. View

4.
Shao J, Chow S . Reproducibility probability in clinical trials. Stat Med. 2002; 21(12):1727-42. DOI: 10.1002/sim.1177. View

5.
Chow S, Shao J . Analysis of clinical data with breached blindness. Stat Med. 2004; 23(8):1185-93. DOI: 10.1002/sim.1694. View